Healthcare-associated Infectious Disease Diagnostics Market Report – Research, Industry Analysis Reports and Market Demands

Global Healthcare-associated Infectious Disease Diagnostics Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

2 Company Profiles

3 Market Competition, by Players

3.1 Global Healthcare-associated Infectious Disease Diagnostics Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of Healthcare-associated Infectious Disease Diagnostics by Company Revenue
- 3.2.2 Top 3 Healthcare-associated Infectious Disease Diagnostics Players Market Share in 2025
- 3.2.3 Top 6 Healthcare-associated Infectious Disease Diagnostics Players Market Share in 2025
3.3 Healthcare-associated Infectious Disease Diagnostics Market: Overall Company Footprint Analysis
- 3.3.1 Healthcare-associated Infectious Disease Diagnostics Market: Region Footprint
- 3.3.2 Healthcare-associated Infectious Disease Diagnostics Market: Company Product Type Footprint
- 3.3.3 Healthcare-associated Infectious Disease Diagnostics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

4.1 Global Healthcare-associated Infectious Disease Diagnostics Consumption Value and Market Share by Type (2021-2026)
4.2 Global Healthcare-associated Infectious Disease Diagnostics Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

5.1 Global Healthcare-associated Infectious Disease Diagnostics Consumption Value Market Share by Application (2021-2026)
5.2 Global Healthcare-associated Infectious Disease Diagnostics Market Forecast by Application (2027-2032)

6 North America

6.1 North America Healthcare-associated Infectious Disease Diagnostics Consumption Value by Type (2021-2032)
6.2 North America Healthcare-associated Infectious Disease Diagnostics Market Size by Application (2021-2032)
6.3 North America Healthcare-associated Infectious Disease Diagnostics Market Size by Country
- 6.3.1 North America Healthcare-associated Infectious Disease Diagnostics Consumption Value by Country (2021-2032)
- 6.3.2 United States Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)
- 6.3.3 Canada Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)
- 6.3.4 Mexico Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)

7 Europe

7.1 Europe Healthcare-associated Infectious Disease Diagnostics Consumption Value by Type (2021-2032)
7.2 Europe Healthcare-associated Infectious Disease Diagnostics Consumption Value by Application (2021-2032)
7.3 Europe Healthcare-associated Infectious Disease Diagnostics Market Size by Country
- 7.3.1 Europe Healthcare-associated Infectious Disease Diagnostics Consumption Value by Country (2021-2032)
- 7.3.2 Germany Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)
- 7.3.3 France Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)
- 7.3.5 Russia Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)
- 7.3.6 Italy Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)

8 Asia-Pacific

8.1 Asia-Pacific Healthcare-associated Infectious Disease Diagnostics Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Healthcare-associated Infectious Disease Diagnostics Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Healthcare-associated Infectious Disease Diagnostics Market Size by Region
- 8.3.1 Asia-Pacific Healthcare-associated Infectious Disease Diagnostics Consumption Value by Region (2021-2032)
- 8.3.2 China Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)
- 8.3.3 Japan Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)
- 8.3.4 South Korea Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)
- 8.3.5 India Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)
- 8.3.7 Australia Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)

9 South America

9.1 South America Healthcare-associated Infectious Disease Diagnostics Consumption Value by Type (2021-2032)
9.2 South America Healthcare-associated Infectious Disease Diagnostics Consumption Value by Application (2021-2032)
9.3 South America Healthcare-associated Infectious Disease Diagnostics Market Size by Country
- 9.3.1 South America Healthcare-associated Infectious Disease Diagnostics Consumption Value by Country (2021-2032)
- 9.3.2 Brazil Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)
- 9.3.3 Argentina Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)

10 Middle East & Africa

10.1 Middle East & Africa Healthcare-associated Infectious Disease Diagnostics Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Healthcare-associated Infectious Disease Diagnostics Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Healthcare-associated Infectious Disease Diagnostics Market Size by Country
- 10.3.1 Middle East & Africa Healthcare-associated Infectious Disease Diagnostics Consumption Value by Country (2021-2032)
- 10.3.2 Turkey Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)
- 10.3.4 UAE Healthcare-associated Infectious Disease Diagnostics Market Size and Forecast (2021-2032)

11 Market Dynamics

11.1 Healthcare-associated Infectious Disease Diagnostics Market Drivers
11.2 Healthcare-associated Infectious Disease Diagnostics Market Restraints
11.3 Healthcare-associated Infectious Disease Diagnostics Trends Analysis
11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

12.1 Healthcare-associated Infectious Disease Diagnostics Industry Chain
12.2 Healthcare-associated Infectious Disease Diagnostics Upstream Analysis
12.3 Healthcare-associated Infectious Disease Diagnostics Midstream Analysis
12.4 Healthcare-associated Infectious Disease Diagnostics Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology
14.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Healthcare-associated Infectious Disease Diagnostics market size was valued at US$ 26692 million in 2025 and is forecast to a readjusted size of US$ 36133 million by 2032 with a CAGR of 4.5% during review period.
Healthcare-associated Infectious Disease Diagnostics refers to an in-vitro diagnostic product and technology system used to detect, identify, type, and clinically interpret infections that occur or spread in hospitals, long-term care facilities, ambulatory surgery centers, dialysis centers, intensive care units, and other healthcare settings. It uses diagnostic reagents, instruments, microbiology identification platforms, antimicrobial susceptibility testing, molecular testing, immunoassays, quality-control systems, and informatics tools to analyze pathogens, resistance genes, toxins, antigens, antibodies, or host inflammatory markers in blood, respiratory specimens, urine, wound secretions, catheter tips, cerebrospinal fluid, stool, and environmental samples. It serves hospital infection surveillance, severe infection diagnosis, antimicrobial stewardship, isolation decisions, outbreak tracing, and healthcare quality control, forming a critical infrastructure for improving patient safety, reducing healthcare-associated transmission, and optimizing anti-infective therapy.The average gross profit margin of this product is 53%.
Healthcare-associated infectious disease diagnostics is evolving from a traditional infection-control tool into a key segment supporting patient safety, hospital quality management, antimicrobial stewardship, and public health resilience. As intensive care, oncology therapy, interventional procedures, organ transplantation, dialysis, and long-term elderly care continue to expand, vulnerable patient populations are increasing, driving sustained demand for rapid identification of bloodstream infections, ventilator-associated infections, catheter-related infections, surgical site infections, urinary tract infections, and multidrug-resistant organisms. Government policies continue to strengthen infectious disease surveillance, healthcare infection prevention, and laboratory testing capacity, while hospital management is shifting from post-event response toward active screening, real-time monitoring, and data-driven early warning. For companies, this field combines high clinical value, strict compliance requirements, and long-term hospital customer stickiness, making it an important growth entry point for the integration of microbiology, molecular diagnostics, and informatics platforms.The core challenges of this industry lie in complex pathogens, diverse sample types, rapidly evolving resistance mechanisms, difficult clinical interpretation, and long hospital procurement decision chains. Healthcare-associated infections often involve bacteria, fungi, viruses, or mixed infections, and are frequently associated with resistance genes, low pathogen loads, and complicated underlying diseases, placing higher requirements on testing sensitivity, specificity, antimicrobial susceptibility consistency, and report interpretation. Microbiological culture has longer turnaround times, molecular testing faces higher cost and platform-adaptation requirements, while rapid testing must balance speed, accuracy, and clinical usability. At the same time, hospital-acquired infection diagnostics are strongly influenced by hospital budgets, healthcare cost control, tender policies, and clinical-department awareness. Companies must build barriers through clinical evidence, product stability, service responsiveness, and data-management capability.Downstream demand is shifting from passive sample submission toward active screening, rapid diagnosis, resistance monitoring, and closed-loop management. Large general and specialty hospitals focus on high-risk settings such as intensive care units, hematology departments, oncology departments, transplant centers, operating rooms, dialysis centers, and neonatal units. They aim to shorten diagnostic time, optimize isolation measures, and guide precise medication through rapid etiological testing, antimicrobial susceptibility testing, resistance gene detection, and infection-control data platforms. Primary hospitals and long-term care facilities need testing solutions that are easy to operate, clear in results, and suitable for initial screening. Independent clinical laboratories and regional testing centers emphasize batch testing, standardized workflows, and regional resistance surveillance. In the future, healthcare-associated infectious disease diagnostics will become a core node in hospital infection management, antimicrobial stewardship, and healthcare quality evaluation systems.
This report is a detailed and comprehensive analysis for global Healthcare-associated Infectious Disease Diagnostics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Healthcare-associated Infectious Disease Diagnostics market size and forecasts, in consumption value ($ Million), 2021-2032
Global Healthcare-associated Infectious Disease Diagnostics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Healthcare-associated Infectious Disease Diagnostics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Healthcare-associated Infectious Disease Diagnostics market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Healthcare-associated Infectious Disease Diagnostics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Healthcare-associated Infectious Disease Diagnostics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BD, Danaher, Abbott, bioMérieux, Hologic, Thermo Fisher Scientific, Roche, DiaSorin, QuidelOrtho, Siemens Healthineers, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Healthcare-associated Infectious Disease Diagnostics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Blood Sample
Respiratory Sample
Urine Sample
Other
Market segment by Technology
Molecular Diagnostics
Immunodiagnostics
Culture & AST
POCT Rapid Tests
Other
Market segment by Test Item
Respiratory Infections
Hepatitis & Blood-borne
Sexually Transmitted Infections
Gastrointestinal Infections
Other
Market segment by Application
Public Hospitals
Third-party Independent Laboratory
Other
Market segment by players, this report covers
BD
Danaher
Abbott
bioMérieux
Hologic
Thermo Fisher Scientific
Roche
DiaSorin
QuidelOrtho
Siemens Healthineers
Qiagen
Bio-Rad
Wondfo Biotech
Autobio
Daan Gene
Innovita
Hybribio
BioPerfectus
Sansure
Liferiver
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Healthcare-associated Infectious Disease Diagnostics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Healthcare-associated Infectious Disease Diagnostics, with revenue, gross margin, and global market share of Healthcare-associated Infectious Disease Diagnostics from 2021 to 2026.
Chapter 3, the Healthcare-associated Infectious Disease Diagnostics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Healthcare-associated Infectious Disease Diagnostics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Healthcare-associated Infectious Disease Diagnostics.
Chapter 13, to describe Healthcare-associated Infectious Disease Diagnostics research findings and conclusion.

Buy now